UroGen Pharma
URGN
138 hedge funds and large institutions have $386M invested in UroGen Pharma in 2024 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 42 increasing their positions, 39 reducing their positions, and 20 closing their positions.
302% more call options, than puts
Call options by funds: $896K | Put options by funds: $223K
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
50% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 20
8% more funds holding
Funds holding: 128 → 138 (+10)
2.54% more ownership
Funds ownership: 83.42% → 85.96% (+2.5%)
8% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 39
13% less capital invested
Capital invested by funds: $446M → $386M (-$59.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$20.9M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$16.4M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$14.7M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$10.5M |
| 5 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$16.9M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$15M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.2M |
| 4 |
Millennium Management
New York
|
-$10.2M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.67M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CSS
151
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$170K | -13,361 | Closed |
|
|
NS
152
NBC Securities
Birmingham,
Alabama
| – | -$8K | -647 | Closed |
|
153
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$6.35K | -500 | Closed |
|
154
Russell Investments Group
London,
United Kingdom
| – | -$3.21K | -253 | Closed |
|
|
TWD
155
True Wealth Design
Akron,
Ohio
| – | -$2.04K | -161 | Closed |
|
|
CPA
156
Capital Performance Advisors
Walnut Creek,
California
| – | -$1.75K | -138 | Closed |
|
157
Bessemer Group
Woodbridge,
New Jersey
| – | -$1K | -85 | Closed |
|
|
AAP
158
Arax Advisory Partners
Denver,
Colorado
| – | -$712 | -56 | Closed |
|
URGN Hedge Fund Activity: Q4 2024 in Review
138 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2024, worth a combined $386M — down 13% from $446M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new URGN positions and 20 closed out — a net gain of 10 holders — while 42 added to existing stakes and 39 trimmed.
The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $20.9M. The largest seller was Morgan Stanley, cutting an estimated $16.9M.
- 138 institutional investors held UroGen Pharma (URGN) as of Q4 2024, up from 128 in Q3 2024.
- Funds reported $386M of UroGen Pharma stock for Q4 2024, down 13% quarter-over-quarter.
- 30 funds opened new UroGen Pharma positions in Q4 2024 and 20 closed out, a net change of +10 holders.
- The largest UroGen Pharma buyer in Q4 2024 was Toronto Dominion Bank, an estimated $20.9M added.
- The largest UroGen Pharma seller in Q4 2024 was Morgan Stanley, an estimated $16.9M sold.
Based on aggregated 13F filings for Q4 2024.